258 reports of this reaction
2.5% of all VIBEGRON reports
#6 most reported adverse reaction
URINARY RETENTION is the #6 most commonly reported adverse reaction for VIBEGRON, manufactured by Sumitomo Pharma America, Inc.. There are 258 FDA adverse event reports linking VIBEGRON to URINARY RETENTION. This represents approximately 2.5% of all 10,281 adverse event reports for this drug.
Patients taking VIBEGRON who experience urinary retention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URINARY RETENTION is a less commonly reported adverse event for VIBEGRON, but still significant enough to appear in the safety profile.
In addition to urinary retention, the following adverse reactions have been reported for VIBEGRON:
The following drugs have also been linked to urinary retention in FDA adverse event reports:
URINARY RETENTION has been reported as an adverse event in 258 FDA reports for VIBEGRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
URINARY RETENTION accounts for approximately 2.5% of all adverse event reports for VIBEGRON, making it a notable side effect.
If you experience urinary retention while taking VIBEGRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.